SML3669
F-1394
≥98% (HPLC)
别名:
(1S,2S)-2-(3-neopentyl-3-nonylureido)cyclohexyl 3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanoate, F 1394, F1394, N-[[(4R)-2,2,5,5-Tetramethyl-1,3-dioxan-4-yl]carbonyl]-β-alanine (1S,2S)-2-[[[(2,2-dimethylpropyl)nonylamino]carbonyl]amino]cyclohexyl ester
InChI key
NWLFOBZKYXKBOF-NSVAZKTRSA-N
SMILES string
CCCCCCCCCN(C(N[C@H]1CCCC[C@@H]1OC(CCNC([C@H]2C(C)(COC(C)(O2)C)C)=O)=O)=O)CC(C)(C)C
assay
≥98% (HPLC)
form
(Powder or solid or semi-solid or liquid)
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
F1394 is an orally available, potent and selective Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor that reduces plaque foam cell formation without inflammatory or toxic effects.
Orally available, potent and selective Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
T Chiwata et al.
British journal of pharmacology, 133(7), 1005-1012 (2001-08-07)
The acyl-CoA:cholesterol acyltransferase (ACAT) enzyme is thought to be responsible for foam cell formation and the subsequent progression of atherosclerosis. The apolipoprotein E and low density lipoprotein receptor double knockout (apoE/LDLr-DKO) mouse is an animal model that develops severe hyperlipidaemia
Jaume Amengual et al.
Molecular pharmacology, 99(3), 175-183 (2021-01-02)
Acyl-CoA:cholesterol acyltransferase (ACAT) mediates cellular cholesterol esterification. In atherosclerotic plaque macrophages, ACAT promotes cholesteryl ester accumulation, resulting in foam cell formation and atherosclerosis progression. Its complete inactivation in mice, however, showed toxic effects because of an excess of free cholesterol
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持